Welcome to our dedicated page for Vor Biopharma SEC filings (Ticker: VOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Deciphering a clinical-stage biotech filing can feel like running a lab experiment without the protocol. Vor Biopharma’s 10-K spans pages of gene-editing details, cash-burn tables, and licensing clauses that leave many investors asking, “Where do I start?”
Stock Titan answers with AI-powered clarity. Our platform scans every new document the second it lands on EDGAR—whether it’s an 8-K material events notice on fresh trial data or a Form 4 insider transaction that hints at executive sentiment. Type a natural question like “understanding Vor Biopharma SEC documents with AI” or “how to read the Vor Biopharma annual report 10-K simplified,” and get plain-English summaries, key financial metrics, and direct page links within seconds.
Here’s what you can explore in one dashboard:
- Vor Biopharma quarterly earnings report 10-Q filing—AI highlights shifts in R&D spend and runway.
- Vor Biopharma insider trading Form 4 transactions—real-time alerts on buys, sells, and option grants.
- Vor Biopharma proxy statement executive compensation—breakdowns of equity awards tied to clinical milestones.
- Vor Biopharma 8-K material events explained—speed-read summaries of trial pauses, FDA designations, or financing rounds.
Need deeper context? Our AI cross-references historical filings for trendlines, delivering a concise Vor Biopharma earnings report filing analysis with year-over-year R&D and dilution impacts. Investors monitoring “Vor Biopharma Form 4 insider transactions real-time” or evaluating risk factors no longer have to sift through biotech jargon—Stock Titan surfaces what matters so you can focus on decisions, not documents.
Vor Biopharma Inc. entered into a private securities purchase agreement with institutional investors to sell 13,876,032 shares of common stock at $10.81 per share, raising gross proceeds of about $150.0 million. The company plans to use the net proceeds to advance its clinical pipeline and for general corporate purposes.
Vor also agreed to a registration rights agreement requiring it to file a resale registration statement for these shares on Form S-3 and to seek effectiveness within set deadlines, with liquidated damages owed to investors if deadlines are missed. Separately, director Sarah Reed resigned, and the board appointed Andrew Levin as an independent Class II director and Wouter Joustra as an independent Class III director, with both receiving the standard non-employee director cash and equity compensation and entering into the company’s standard indemnification agreements.
Vor Biopharma Inc. reported an insider equity update involving its officer serving as CFO. On December 5, 2025, the company’s compensation committee approved the cancellation of 694,137 restricted stock units, leaving the reporting person with no directly held common stock after the transaction.
On the same date, the CFO acquired an employee stock option1,388,274 shares of common stock, expiring on December 4, 2035. The exercise price is $17.80 per share, or $8.18 per share if the option is exercised after a defined “Retention Period” that runs from December 5, 2025 through the earlier of December 5, 2027 or a qualifying change in control during continuous service. One quarter of the option vests on July 1, 2026, with the rest vesting in equal monthly installments over three years, subject to continued service. Share counts reflect a 1-for-20 reverse stock split completed on September 18, 2025.
Vor Biopharma Inc. filed its Q3 2025 10‑Q, highlighting a pivot to autoimmune diseases centered on telitacicept and significant non‑cash items that dominated results. The company reported a net loss of $812.7 million for the quarter and $2,418.8 million for the nine months, largely driven by a $790.5 million quarterly and $2,090.4 million year‑to‑date change in the fair value of liability‑classified warrants.
Operating expenses were $28.1 million in Q3, including $14.1 million for R&D and $14.0 million for G&A. Year‑to‑date, R&D includes a $222.6 million charge for the telitacicept license (cash $45.0 million plus a warrant initially valued at $177.4 million) and $29.7 million of restructuring costs tied to the wind‑down of prior programs and a lease termination.
Cash, cash equivalents and marketable securities were $170.5 million as of September 30, 2025. Subsequent financings added $49.8 million via an October at‑the‑market sale and approximately $93.7 million from a November underwritten offering, with an additional $14.1 million expected from the overallotment. Management projects liquidity to fund operations into the second quarter of 2027.
Vor Biopharma Inc. announced a public equity offering of 10,000,000 shares at $10.00 per share. The Company expects net proceeds of approximately $93.7 million, or $107.8 million if underwriters exercise a 30-day option to purchase up to 1,500,000 additional shares, with closing expected on November 12, 2025, subject to customary conditions.
Vor plans to use proceeds to advance telitacicept clinical development, including initiation of a Phase 3 trial for primary Sjögren’s Disease, along with manufacturing, pre-commercialization, working capital and general corporate purposes. Including $49.8 million of net proceeds from recent ATM sales, the Company believes its cash resources will fund operations into the second quarter of 2027. Shares outstanding were 9,026,922 as of September 30, 2025.
Vor Biopharma (VOR) launched a primary offering of 10,000,000 shares of common stock at $10.00 per share, a follow-on under its shelf registration. The deal includes a 30‑day option for underwriters to purchase up to 1,500,000 additional shares. The pricing table lists a public offering price of $10.00, underwriting discounts of $0.60 per share, and proceeds to the company of $9.40 per share before expenses. Vor estimates net proceeds of approximately $93.7 million after fees and expenses.
The company plans to use proceeds to advance telitacicept, including a Phase 3 trial in primary Sjögren’s disease, plus manufacturing, pre‑commercialization, working capital and general corporate purposes. Vor noted it is an emerging growth and smaller reporting company and completed a 1‑for‑20 reverse stock split on September 18, 2025. The company agreed to a 60‑day lock‑up (90 days for directors, officers and certain stockholders) and to pause sales under its ATM program for 30 days unless the underwriters’ option is exercised in full.
Vor Biopharma (VOR) launched a primary offering of $100,000,000 of common stock, with underwriters granted a 30‑day option to purchase up to an additional $15,000,000 of shares. The company’s stock trades on Nasdaq as “VOR.” On November 7, 2025, the last reported sale price was $18.70 per share. All share figures reflect the 1‑for‑20 reverse split effected on September 18, 2025.
Vor plans to use net proceeds to advance telitacicept, including a Phase 3 trial in primary Sjögren’s disease, manufacturing and pre‑commercialization activities, and for working capital and general corporate purposes. The company and certain insiders agreed to lock‑ups (company 60 days; directors, officers and certain stockholders 90 days). Vor also agreed not to sell under its ATM program for 30 days after this offering unless the underwriters’ option is exercised in full.
Shares outstanding were 6,282,297 as of June 30, 2025. This figure provides a baseline and is separate from the amount being offered.
Vor Biopharma Inc. filed Amendment No. 1 to its Form S-3, covering the resale by selling stockholders of up to 50,999,999 shares of common stock after effectiveness. The amendment adds Rule 473(b) language for automatic effectiveness 20 days after filing.
The shares consist of up to 16,000,000 issuable upon exercise of the RemeGen Warrant and up to 34,999,999 issuable upon exercise of PIPE Warrants; all figures reflect the 1-for-20 reverse stock split effected on September 18, 2025. The company will not receive proceeds from stockholder resales; it would receive cash only upon warrant exercises at $0.002 per share, totaling approximately $102,000 if fully exercised for cash. Examples of registered resale amounts include RemeGen Co., Ltd. 16,000,000 and RA Capital Healthcare Fund, L.P. 10,000,000. Shares outstanding were 6,853,907 as of September 18, 2025.
Vor Biopharma (VOR) amended the employment agreement of Chief Development Officer Dr. Qing Zuraw, effective November 2, 2025, for a five‑month period. If she is terminated without cause, she will receive a lump-sum, pro‑rated portion of her 2025 target bonus and, if applicable, a pro‑rated portion of her 2026 target bonus. If she resigns for any reason after December 31, 2025, she will receive the same severance benefits as a without‑cause termination.
The company also announced the appointment of Dr. Jeremy Sokolove as Chief Medical Officer via a November 3, 2025 press release furnished under Regulation FD.
Vor Biopharma (VOR): RA Capital-affiliated reporting persons, identified as a director and 10% owner, reported open-market sales of common stock on October 28–30, 2025.
Disclosed transactions: 87,828 shares at a weighted average price of $27.10; 36,483 shares at $28.18; 251,518 shares at $25.22; and 24,579 shares at $25.12. After these trades, 779,652 shares were beneficially owned indirectly. Prices reflect weighted averages across multiple trades within stated ranges. The shares are held directly by RA Capital Healthcare Fund, L.P., with beneficial ownership disclaimed except to the extent of pecuniary interest.
Vor Biopharma furnished a Regulation FD update via an 8-K. On October 28, 2025, the company hosted a webcast to discuss late‑breaking 48‑week Phase 3 clinical trial data from China for telitacicept in primary Sjögren’s disease. The presentation used in the webcast was furnished as Exhibit 99.1 and is not deemed filed under the Exchange Act.
FAQ
What is the current stock price of Vor Biopharma (VOR)?
What is the market cap of Vor Biopharma (VOR)?
